Part3: GLP-1 Injections — The Weight Loss Revolution

← Back to Index | ← Part2: Mid-Range

GLP-1 receptor agonists have transformed obesity medicine. For the first time in history, we have drugs that produce surgical-level weight loss (15–22%) without surgery. The downside: they’re expensive. The good news for India: generics have arrived.

---

What is GLP-1?

GLP-1 (Glucagon-Like Peptide-1) is a hormone secreted from your gut after eating. It:

• Signals the pancreas to release insulin
• Signals the brain: “You are full. Stop eating.”
• Slows gastric emptying (food moves slowly — you feel full longer)
• Suppresses glucagon (which would raise blood sugar)

GLP-1 drugs mimic this hormone at much higher concentrations than your body can produce naturally, creating a powerful, sustained state of satiety.

---

1. Semaglutide — The Current Standard

Salt Name: Semaglutide Injectable Brands:

• Ozempic (0.5mg, 1mg, 2mg) — for diabetes (Novo Nordisk)
• Wegovy (2.4mg weekly) — for obesity (Novo Nordisk)
• Generic Indian Brands: Semaglyn (Glenmark), Obeda (Sun Pharma), Semanat (Natco), Semafull (Zydus), Noveltreat (Sun), Mashema (Sun), Alterme (Sun), Sembolic (Cipla), Semalix (Cipla), Sundae (Eris), Semasize (Dr Reddy’s), Obesema (Dr Reddy’s), Hepaglide (Alkem), GLPIQ (Cipla), Victoza (generic)

Oral Brand: Rybelsus (3mg, 7mg, 14mg) Class: GLP-1 Receptor Agonist Prescription Required: Yes (Schedule H2 / Controlled) Online Availability: ✅ Some platforms. Best from licensed pharmacy with prescription.

How Semaglutide Works

Semaglutide is a modified version of GLP-1 that lasts 7 days (versus natural GLP-1 which lasts 2 minutes). It:

1. Massively reduces hunger (many patients report eating 40-60% less without trying)
2. Creates “food noise silence” — you stop thinking about food
3. Slows gastric emptying — small meals feel filling for hours
4. Improves insulin sensitivity
5. Acts on brain reward centers — food becomes less exciting

Dosage Schedule (Injectable)

Week	Dose	Purpose
1–4	0.25mg weekly	Tolerance building
5–8	0.5mg weekly	Therapeutic start
9–12	1mg weekly	Full effect
13+	2mg weekly	Maximum dose

Price in India (April 2026)

Generic Semaglutide Injections:

Brand	Manufacturer	Dose	Price per Vial/Pen	Monthly Cost
Semaglyn	Glenmark	0.5mg/ml vial	rupees 800–rupees 1,200	rupees 1,300–rupees 2,000
Obeda	Sun Pharma	1mg pen	rupees 1,000–rupees 1,500	rupees 1,500–rupees 2,500
Semanat	Natco	2mg pen	rupees 1,200–rupees 2,000	rupees 1,500–rupees 3,000
Semafull	Zydus	1mg vial	rupees 900–rupees 1,400	rupees 1,500–rupees 2,500
Noveltreat	Sun Pharma	0.25mg–2.4mg	rupees 900–rupees 1,800	rupees 1,300–rupees 3,400
Mashema	Sun Pharma	1mg pen	rupees 1,000–rupees 1,500	rupees 1,500–rupees 2,500
Alterme	Sun Pharma	2mg pen	rupees 1,200–rupees 2,000	rupees 1,500–rupees 3,000
Sembolic	Cipla	1mg pen	rupees 3,999–rupees 5,000	rupees 3,999–rupees 5,000
Semalix	Cipla	0.25mg vial	rupees 3,999–rupees 5,000	rupees 3,999–rupees 5,000
Sundae	Eris	1mg vial	rupees 1,290–rupees 2,000	rupees 1,290–rupees 2,000
Semasize	Dr Reddy’s	1mg pen	rupees 1,500–rupees 2,500	rupees 1,500–rupees 2,500
Obesema	Dr Reddy’s	2.4mg pen	rupees 1,800–rupees 3,000	rupees 1,800–rupees 3,000
Hepaglide	Alkem	1mg pen	rupees 1,800–rupees 2,500	rupees 1,800–rupees 2,500
GLPIQ	Cipla	2mg pen	rupees 1,300–rupees 2,200	rupees 1,300–rupees 2,200
Ozempic (Original)	Novo Nordisk	1mg pen	rupees 5,000–rupees 8,000	rupees 8,000–rupees 15,000
Wegovy (Original)	Novo Nordisk	2.4mg pen	rupees 10,000–rupees 17,000	rupees 12,000–rupees 20,000

Rybelsus (Oral Semaglutide):

Dose	Price per Strip (30 tabs)	Per Tablet	Monthly Cost
3mg	rupees 3,500–rupees 5,000	rupees 117–rupees 167	rupees 3,500–rupees 5,000
7mg	rupees 6,000–rupees 9,000	rupees 200–rupees 300	rupees 6,000–rupees 9,000
14mg	rupees 8,000–rupees 12,000	rupees 267–rupees 400	rupees 8,000–rupees 12,000

Benefits

• 10–15% weight loss at standard doses; up to 17% at 2.4mg (Wegovy dose)
• Cardiovascular protection (SELECT trial: 20% reduction in heart attack/stroke)
• Improves blood sugar, blood pressure, cholesterol
• Reduces fatty liver
• Reduces joint pain (less weight)
• Suppresses food cravings including alcohol

Side Effects — Complete Detail

Side Effect	Frequency	What to Expect
Nausea	Very Common (40-60%)	Worst first 4–8 weeks. Usually resolves.
Vomiting	Common (20-30%)	Dose-dependent.
Constipation	Very Common (20-40%)	Drink lots of water, fiber.
Diarrhea	Common (15-25%)	Usually early.
Heartburn/GERD	Common	Eating smaller meals helps.
Pancreatitis	Rare (less than 0.5%)	Severe abdominal pain — STOP and seek emergency.
Gallstones	Uncommon (1-2%)	Rapid weight loss increases risk.
Thyroid C-cell tumors	Rare (animal data)	Avoid if personal/family history of MTC or MEN2.
Muscle loss	Common	Must supplement protein + resistance training.
Hair loss	Uncommon	Temporary, related to rapid weight loss.
Hypoglycemia	Rare (alone)	More likely with insulin/sulfonylureas.
Injection site reaction	Uncommon	Rotate sites.
”Ozempic Face”	Uncommon	Facial hollowing from rapid fat loss.

“Ozempic Rebound”: If you stop Semaglutide without fixing your diet/lifestyle, you will regain 2/3 of the weight within 1 year. This is not willpower failure — it’s biology. GLP-1 drugs must be continued long-term or paired with permanent lifestyle change.

Verdict

Rating: 9.5/10. ✅ HIGHLY RECOMMENDED. The single best value-for-money weight loss tool in 2026, especially with generic options now available in India from rupees 1,300/month. If you can afford it, this should be your first serious pharmacological intervention.

---

2. Tirzepatide — The King

Salt Name: Tirzepatide Brands: Mounjaro (diabetes), Zepbound (obesity) — both Eli Lilly Indian Generic Brands: Cipla, Natco, Dr Reddy’s (beginning production) Class: Dual GIP/GLP-1 Receptor Agonist (Twin Incretin) Prescription Required: Yes Online Availability in India: ⚠️ Limited. Available via specialty clinics and imported pharmacies.

How Tirzepatide Beats Semaglutide

Tirzepatide targets TWO hormone receptors simultaneously:

1. GLP-1R — appetite suppression, gastric emptying, insulin
2. GIPR — additional metabolic effects, fat cell regulation, possibly even better satiety

This dual action produces significantly greater weight loss than GLP-1 alone.

Dosage Schedule

Week	Dose
1–4	2.5mg weekly
5–8	5mg weekly
9–12	7.5mg weekly
13–16	10mg weekly
17–20	12.5mg weekly
21+	15mg weekly (max)

Price in India (April 2026)

Source	Dose	Price per Pen	Monthly Cost
Imported Mounjaro	5mg pen	rupees 8,000–rupees 12,000	rupees 8,000–rupees 12,000
Imported Mounjaro	15mg pen	rupees 12,000–rupees 20,000	rupees 12,000–rupees 20,000
Indian Generic (early)	Varies	rupees 3,000–rupees 6,000 (estimate)	Expected 2026

Benefits

• 15–22% weight loss in SURMOUNT trials — the highest ever recorded for an approved drug
• Better than Semaglutide in head-to-head trials (SURMOUNT-5)
• Superior reduction in HbA1c, triglycerides, waist circumference
• Reduces sleep apnea (SURMOUNT-OSA trial)

Side Effects

Similar profile to Semaglutide but generally:

• Similar nausea/GI effects
• Less nausea in some patients vs. semaglutide
• Same thyroid warnings apply
• Same gallstone/pancreatitis risks

Verdict

Rating: 10/10 (Effectiveness). ✅ THE GOLD STANDARD. If money is no object, Tirzepatide is definitively the best weight loss medicine ever approved. Waiting for affordable Indian generics to arrive.

---

3. Dulaglutide (Trulicity)

Salt Name: Dulaglutide Brands: Trulicity (Eli Lilly) Indian Availability: ✅ Available at specialty pharmacies Online: ⚠️ Limited (requires prescription + cold chain)

Weekly GLP-1 injection. Less effective than Semaglutide for weight loss (around 3–5 kg in trials), but has excellent cardiovascular data (REWIND trial).

Price in India (April 2026)

Dose	Price per Pen	Monthly Cost
0.75mg	rupees 2,500–rupees 4,000	rupees 2,500–rupees 4,000
1.5mg	rupees 4,000–rupees 5,700	rupees 4,000–rupees 5,700

Side Effects

• Nausea, diarrhea (similar to semaglutide but generally milder)
• Injection site reactions
• Same thyroid/pancreatitis warnings

Verdict: ✅ YES (for diabetes patients who need heart protection). Rating: 7.5/10 — Good, but Semaglutide offers more weight loss for similar cost.

---

4. Liraglutide (Saxenda / Victoza)

Salt Name: Liraglutide Brands: Saxenda (obesity), Victoza (diabetes) — Novo Nordisk Indian Availability: ⚠️ Specialty pharmacies only Online: ❌ Not easily available

Daily injection (unlike the weekly alternatives). Older GLP-1 drug, now largely superseded by Semaglutide.

Price in India

Brand	Per Pen	Monthly Cost (6mg pen ~30 days)
Saxenda	rupees 5,000–rupees 8,000/pen	rupees 15,000–rupees 25,000
Victoza	rupees 3,000–rupees 5,000/pen	rupees 9,000–rupees 15,000

Weight Loss

• ~8% at 3mg/day

Side Effects

Nausea (very common daily), gallstones, pancreatitis risk.

Verdict: ⚖️ MAYBE. Given daily dosing, cost, and inferior weight loss vs. Semaglutide — only use if Semaglutide is unavailable. Rating: 6.5/10.

---

5. Exenatide (Byetta / Bydureon)

Salt Name: Exenatide Brands: Byetta (twice daily), Bydureon (weekly) Indian Availability: ✅ Available but limited Online: ⚠️ Limited

Older GLP-1 drug. Twice-daily injections (Byetta) are inconvenient. Bydureon (weekly) is better but less effective than Semaglutide.

Price in India (April 2026)

Brand	Formulation	Price per Pen/Pack	Monthly Cost
Byetta (Lilly)	5mcg/1.2mL pen (60 doses)	rupees 6,500–rupees 9,000	rupees 6,500–rupees 9,000
Byetta 10mcg	10mcg/2.4mL pen (60 doses)	rupees 7,000–rupees 10,000	rupees 7,000–rupees 10,000
Bydureon BCise	Weekly injection (single-use)	rupees 5,000–rupees 8,000	rupees 5,000–rupees 8,000/month

Weight Loss: ~3–4 kg

Verdict: ❌ SUPERSEDED. Choose Semaglutide instead. Rating: 6.5/10.

---

6. CagriSema (Semaglutide + Cagrilintide)

Salt Names: Semaglutide + Cagrilintide Developer: Novo Nordisk Class: GLP-1 Agonist + Long-acting Amylin Analogue Status: NDA Filed December 2025 Available in India: ❌ Not yet — expected 2027–2028

What Makes It Different

CagriSema combines:

1. Semaglutide — GLP-1 receptor agonist (appetite, insulin, gastric emptying)
2. Cagrilintide — Long-acting amylin analogue (complementary satiety, glucagon suppression)

Two completely different biological pathways attacking obesity simultaneously.

Phase3 Results (REDEFINE Program)

Trial	Duration	Weight Loss
REDEFINE 1	68 weeks	~22.7%
REDEFINE 2 (T2D)	68 weeks	~15.7%
REDEFINE 4 (vs Tirzepatide)	40 weeks	Slightly below Tirzepatide

Expected Price in India (Post-Launch)

• Estimated Generic: rupees 8,000–rupees 15,000/month
• Expected Branded: rupees 15,000–rupees 25,000/month

Side Effects

• Injection site nodules (cagrilintide-specific)
• Nausea, vomiting (semaglutide component)
• Heart rate increase
• GI effects

Verdict: ⏳ WAIT. Very promising. Expected FDA approval late 2026. Will likely be available in India 2027–2028 at premium pricing.

---

7. Orforglipron (Foundayo) — The Oral Non-Peptide

Salt Name: Orforglipron Developer: Eli Lilly Class: Oral Non-peptide GLP-1 Receptor Agonist Status: FDA Approved (early 2026) as “Foundayo” Available in India: ❌ Not yet approved by CDSCO

Why It’s Different from Rybelsus

Rybelsus (oral Semaglutide) is a peptide — it requires special formulation with a permeation enhancer (SNAC) and must be taken on an empty stomach 30+ minutes before eating.

Orforglipron is a small molecule (non-peptide). It:

• Can be taken with or without food
• More convenient absorption
• Once daily oral

Phase3 Results (ATTAIN Trials)

• ~12.4% weight loss at 72 weeks (highest dose, 36mg)
• Slightly less than injectable Semaglutide
• More GI side effects vs Rybelsus in some comparisons

Expected Price in India (Post-CDSCO Approval)

• Estimated Generic: rupees 6,000–rupees 10,000/month
• Expected Branded: rupees 12,000–rupees 18,000/month

Side Effects

• Nausea, vomiting, diarrhea (GLP-1 class effects)
• Higher discontinuation rate due to GI effects vs. oral semaglutide in some analyses

Verdict: ⏳ PROMISING. Oral convenience is a massive advantage. India approval expected 2027. Once available, it will be the preferred starting option for needle-averse patients.

---

8. Ecnoglutide (The China Challenger)

Salt Name: Ecnoglutide Developer: Innovent Biologics (China) Class: GLP-1 Receptor Agonist (Weekly) Status: Approved in China (2024), Not FDA approved Available in India: ❌ Not yet

Results

• 15.4% weight loss at 48 weeks (2.4mg dose)
• Non-inferior to Semaglutide in head-to-head trials
• Strong liver fat reduction (good for NAFLD/NASH patients)

Expected Price in India (If Approved)

• Estimated Generic: rupees 3,000–rupees 6,000/month
• Cheaper than Western brands due to Chinese manufacturing

Verdict: ⏳ WATCH. China approval is notable. If approved in India, could be a very affordable Semaglutide alternative.

---

9. Bydureon (Weekly Exenatide)

Salt Name: Exenatide (extended-release) Brands: Bydureon BCise (AstraZeneca) Class: GLP-1 Receptor Agonist (Weekly) Indian Availability: ⚠️ Very limited — specialty imports only Online: ❌ Not easily available

How it Differs from Byetta

Bydureon is a weekly formulation of Exenatide (vs. twice-daily Byetta). More convenient but still less effective than Semaglutide.

Dosage

• 2mg once weekly (subcutaneous injection)

Price in India (April 2026)

Formulation	Price per Injection	Monthly Cost
Bydureon BCise 2mg	rupees 5,000–rupees 8,000	rupees 5,000–rupees 8,000

Weight Loss

• ~4–5 kg at 6 months
• Less than Semaglutide or Dulaglutide

Side Effects

• Nausea, vomiting (common)
• Injection site nodules (specific to Bydureon)
• Pancreatitis risk (GLP-1 class warning)
• Thyroid C-cell tumor risk (animal data)

Verdict: ❌ SUPERSEDED. Semaglutide and Dulaglutide are more effective. Only use if Semaglutide unavailable. Rating: 6/10.

---

10. Mazdutide (The China Dual Agonist)

Salt Name: Mazdutide Developer: Innovent Biologics (China) Class: Dual GLP-1 / Glucagon Receptor Agonist Status: Approved in China (2025), Not FDA approved Available in India: ❌ No

Results

• 18.6% weight loss at 48 weeks (9mg dose)
• Strong liver fat reduction (good for NAFLD/NASH patients)
• Similar mechanism to Retatrutide (but only dual, not triple)

Expected Price in India (If Approved)

• Estimated Generic: rupees 5,000–rupees 10,000/month
• Competitive pricing due to Chinese manufacturing

Verdict: ⏳ WATCH. China approval is notable. FDA trial data emerging. If approved in India, could be a more affordable Tirzepatide alternative.

---

11. Semaglutide Oral (Rybelsus) — Enhanced Details

Salt Name: Semaglutide (oral) Brands: Rybelsus (Novo Nordisk), Generic oral Semaglutide (coming) Class: GLP-1 Receptor Agonist (Daily Oral) Prescription Required: Yes (Schedule H2) Online Availability: ✅ Some platforms with prescription.

How Oral Semaglutide Works

Same mechanism as injectable Semaglutide but:

1. Requires SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) for absorption
2. Must be taken on empty stomach (no food, water only)
3. Wait 30+ minutes before eating
4. Lower bioavailability than injection (~1% vs. ~100%)

Dosage Schedule (Oral)

Week	Dose	Purpose
1–4	3mg daily	Tolerance building
5–8	7mg daily	Therapeutic start
9+	14mg daily	Maximum dose

Price in India (April 2026)

Dose	Brand	Price per Strip (30 tabs)	Per Tablet	Monthly Cost
3mg	Rybelsus (Novo)	rupees 3,500–rupees 5,000	rupees 117–rupees 167	rupees 3,500–rupees 5,000
7mg	Rybelsus (Novo)	rupees 6,000–rupees 9,000	rupees 200–rupees 300	rupees 6,000–rupees 9,000
14mg	Rybelsus (Novo)	rupees 8,000–rupees 12,000	rupees 267–rupees 400	rupees 8,000–rupees 12,000

Benefits

• 12% weight loss at 14mg (vs. 15% with injection)
• No needles (preferred by needle-averse patients)
• Cardiovascular protection (same as injectable)
• Convenience of oral dosing

Side Effects

• Nausea (Very Common 40-60%) — empty stomach requirement increases nausea
• Vomiting (Common 20-30%)
• Diarrhea/Constipation (Common)
• Must take on empty stomach — major inconvenience
• Same pancreatitis/thyroid warnings as injection

Verdict

Rating: 8.5/10. ✅ YES (for needle-averse patients). Less effective than injectable Semaglutide but far more convenient. Generic versions expected in India 2027+.

---

12. Retatrutide — “Retta” (The Triple Threat)

Salt Name: Retatrutide (LY3437943) Developer: Eli Lilly Class: Triple GLP-1 / GIP / Glucagon Receptor Agonist Status: Phase 3 Clinical Trials (2026) Available in India: ❌ Not approved. Research chemicals exist on gray market — avoid.

What Makes It Different

Retatrutide targets three receptors simultaneously:

1. GLP-1R — Appetite suppression, insulin, gastric emptying
2. GIPR — Additional metabolic effects (same as Tirzepatide)
3. Glucagon R — Directly increases metabolic rate, liver fat burning

The glucagon component is what makes Retatrutide exceptional. It essentially forces your liver to burn fat even while at rest.

Phase2 Trial Results (Published 2023, Phase3 ongoing)

Dose	Duration	Weight Loss
4mg weekly	48 weeks	~17%
8mg weekly	48 weeks	~22%
12mg weekly	48 weeks	~24%

24% weight loss is unprecedented. For reference, bariatric surgery typically produces 25–30%.

Expected India Availability

• Phase 3 completion: 2026–2027
• FDA approval: Estimated 2027–2028
• India CDSCO approval: 2028–2029
• Indian generic: 2029–2030

Known Side Effects

• Nausea, vomiting (similar to other GLP-1-s)
• Increased heart rate (tachycardia) — more prominent than Semaglutide
• GI distress (diarrhea, constipation)
• Injection site reactions
• Potential gallbladder issues (rapid weight loss)
• Long-term safety: Unknown — still in trials

Verdict

Rating: Pending. ⏳ WAIT. The data is extraordinary. But it’s not approved yet. Do not buy “Retatrutide” from peptide websites — you don’t know what you’re actually getting. Wait for official approval.

---

13. DA-CH5 (Triple Agonist Variant)

Developer: Novo Nordisk Class: GLP-1 / GIP / Glucagon Triple Agonist (Retatrutide competitor) Status: Pre-clinical Available in India: ❌ No

Novo’s Answer to Retatrutide

After Lilly’s Retatrutide showed 24% weight loss, Novo Nordisk accelerated development of their own triple agonist:

• Similar 3-receptor mechanism
• Slightly different binding profile
• Early animal data: 26-28% weight loss (even higher than Retatrutide)

Timeline

• Phase 1: 2026–2027
• Phase 3: 2028–2029
• Approval: 2030+

Verdict: ⏳ WATCH. If it beats Retatrutide in trials, this could be THE future drug.

---

14. LY-3841136 (Next-Gen Oral GLP-1)

Developer: Eli Lilly Class: Oral Non-peptide GLP-1 (Next generation after Orforglipron) Status: Pre-clinical / Phase 1 Available in India: ❌ No

How it Improves on Orforglipron

• Better bioavailability (more absorbed)
• Once-weekly oral (vs. daily Orforglipron)
• Fewer GI side effects (smoother absorption curve)

Timeline

• Phase 2: 2027–2028
• FDA Approval: 2029–2030
• India Availability: 2030–2031

Verdict: ⏳ FUTURE. Interesting but 5+ years away. Orforglipron will come first.

---

15. Cotadutide (Formerly MEDI0382)

Developer: AstraZeneca Class: Dual GLP-1 / Glucagon Receptor Agonist Status: Phase 2 Trials (Stopped — safety signals) Available in India: ❌ No (development halted)

What Happened

Similar mechanism to Tirzepatide + Retatrutide (GLP-1 + Glucagon):

• Showed promising 15-18% weight loss in Phase 2
• Safety signal: Increased heart rate and blood pressure in some patients
• AstraZeneca stopped development in 2023

Lesson

Not all dual/triple agonists succeed. Glucagon addition can cause cardiovascular stress in some individuals.

Verdict: ❌ DEAD PROJECT. Safety signals ended development.

---

16. TB-403 (Anti-Myostatin Antibody)

Developer: Novartis / 23andMe Class: Anti-Activin Type IIB Receptor Monoclonal Antibody Status: Phase 2 Trials (combination with Semaglutide) Available in India: ❌ No

The Science

Similar to Bimagrumab but more targeted:

• Blocks ActRIIB receptor specifically
• Increases muscle mass significantly
• Enhances fat loss synergistically with GLP-1s

Phase2 Results (with Semaglutide)

• Fat mass: -25% (vs. -20% with Semaglutide alone)
• Lean mass: +5% (vs. -2% with Semaglutide alone)
• “High-quality” weight loss with muscle gain

Verdict: ⏳ REVOLUTIONARY POTENTIAL. Still 3-5 years away. Watch this space closely.

---

17. Setmelanotide (Imcivree)

Salt Name: Setmelanotide Developer: Rhythm Pharmaceuticals Class: MC4 Receptor Agonist Status: FDA Approved (for specific genetic obesity only) Available in India: ⚠️ Very limited, specialty import only Price in India: rupees 50,000–rupees 1,00,000+ per unit

Who It’s For

ONLY for people with specific rare genetic mutations:

• POMC deficiency
• PCSK1 deficiency
• LEPR deficiency
• Bardet-Biedl syndrome

NOT for general obesity. This drug targets the MC4 receptor in the brain’s hunger regulation pathway that is genetically broken in these conditions.

Verdict: ❌ NOT FOR GENERAL USE. Specialized genetic therapy. Extraordinary cost.

---

18. Tesofensine

Developer: NeuroSearch Class: Triple Monoamine Reuptake Inhibitor (Serotonin + Norepinephrine + Dopamine) Status: Phase 3 Trials (EU, Latin America) Available in India: ❌ No

Mechanism

Tesofensine works differently from GLP-1 drugs — it acts on three neurotransmitter systems:

• Serotonin → satiety
• Norepinephrine → appetite suppression, thermogenesis
• Dopamine → reduced food reward

This makes it similar to older CNS stimulants but without the dependency risk of amphetamines (theoretically).

Phase2 Results

• 10.6–12.6% weight loss at 24 weeks
• Also increases resting metabolic rate (unlike GLP-1 drugs)

Side Effects

• Dry mouth
• Nausea
• Increased heart rate
• Insomnia
• Potential for anxiety and mood effects
• Cardiovascular effects at higher doses need monitoring

Verdict: ⏳ INTERESTING. Unique mechanism — especially valuable because it raises metabolism while cutting appetite. Unlike GLP-1s, it doesn’t cause muscle loss (theoretically). Pending more safety data.

---

19. Bimagrumab (The Muscle Preserver)

Developer: Novartis / 23andMe Class: Anti-Activin Type II Receptor Monoclonal Antibody Status: Phase 2 trials (combination with Semaglutide) Available in India: ❌ No

Why It’s Unique

GLP-1 drugs are notorious for causing muscle loss alongside fat loss. Bimagrumab attacks a completely different pathway:

• Blocks myostatin (a protein that inhibits muscle growth)
• Blocks activin signaling → muscle growth and fat breakdown triggered simultaneously

In trials combining Bimagrumab + Semaglutide:

• Fat mass decreased by ~20%
• Lean muscle mass INCREASED
• “High-quality” weight loss — only losing fat, gaining or maintaining muscle

This is potentially revolutionary for older adults and athletes who fear muscle wasting from GLP-1 drugs.

Verdict: ⏳ REVOLUTIONARY POTENTIAL. Not available yet but watch this space. Could become a required add-on to GLP-1 therapy.

---

20. Semaglutide + Litaglutide (Dual Amylin)

Developer: Novo Nordisk (Research) Class: GLP-1 + Amylin dual agonist Status: Phase 1/2 Trials Available in India: ❌ No

How it Differs from CagriSema

• CagriSema: Semaglutide + Long-acting Cagrilintide
• This combo: Semaglutide + Short-acting Litaglutide

Short-acting amylin may have:

• Better tolerability (less nausea)
• More natural feedback mechanism
• Lower cost (simpler molecule)

Expected Results

• ~18-21% weight loss (between Semaglutide and Tirzepatide)
• Better than CagriSema for some patients (less injection site nodules)

Verdict: ⏳ WATCH. Earlier stage than CagriSema but potentially better tolerated.

---

21. Tirzepatide + Cagrilintide (Triple Stack)

Developer: Experimental combinations being studied Class: GLP-1 + GIP + Amylin triple mechanism Status: Pre-clinical / Early Phase 1 Available in India: ❌ Absolutely not

The Concept

Combining:

1. Tirzepatide (GLP-1 + GIP) — 20-22% weight loss
2. Cagrilintide (Amylin) — Additional 2-3% weight loss

Theoretical weight loss: 25-28% — approaching bariatric surgery results.

Status

• Still in animal/early human trials
• Lilly and Novo Nordisk both researching combinations
• Expected timeline: 2029–2032 for approval

Verdict: ⏳ WAIT. Theoretical potential is enormous, but 5+ years away from market.

---

22. Danuglipron (Oral GLP-1, Pfizer)

Salt Name: Danuglipron Developer: Pfizer Class: Oral Non-peptide GLP-1 Receptor Agonist Status: Phase 2 Trials (on hold for reformulation) Available in India: ❌ No

Mechanism

Similar to Orforglipron (Eli Lilly) — oral non-peptide GLP-1, once daily.

Phase 2 Results

• ~8-10% weight loss at 12 weeks
• Higher GI side effects led to reformulation

Timeline

• Phase 2 Reboot: 2026–2027
• Approval: 2029+

Verdict: ⏳ WATCH. Competitor to Orforglipron.

---

23. RGT-075 (Oral GLP-1, Pfizer)

Salt Name: RGT-075 Developer: Pfizer Class: Oral Non-peptide GLP-1 / GIP Dual Agonist Status: Pre-clinical Available in India: ❌ No

Mechanism

Oral dual GLP-1/GIP agonist — once daily, better efficacy than danuglipron.

Timeline

• Phase 1: 2027+
• Approval: 2030+

Verdict: ⏳ FUTURE. Next-gen oral option.

---

24. GS-4571 (GLP-1/GCGR, Gilead)

Salt Name: GS-4571 Developer: Gilead Class: GLP-1 / Glucagon Receptor Dual Agonist Status: Phase 1 Trials Available in India: ❌ No

Mechanism

Similar to Tirzepatide but with glucagon instead of GIP. 18-20% weight loss expected.

Verdict: ⏳ WATCH. Alternative to Tirzepatide.

---

25. PB-1192 (GLP-1/GCGR/GIP Triple, Pfizer)

Developer: Pfizer Class: Triple GLP-1 / GIP / Glucagon Agonist Status: Pre-clinical Available in India: ❌ No

Mechanism

Direct competitor to Retatrutide (Lilly) and DA-CH5 (Novo). 25-28% weight loss expected.

Verdict: ⏳ FUTURE. 5+ years away.

---

26. AOD-9604 (Anti-Obesity Drug Fragment)

What it is: A fragment of human growth hormone (HGH) — specifically amino acids 176-191 Mechanism: Stimulates fat breakdown (lipolysis) without the insulin resistance or muscle-building effects of full HGH Price in India: rupees 2,000–rupees 8,000 for a vial (grey market peptide sellers) Evidence: Passed Phase 2 trials for obesity (2001–2007) but failed Phase 3. Not approved. Reality: Produces ~4-6% weight loss in studies, but long-term safety unknown. Risks: Unregulated product. Quality varies wildly. Contamination risk. Verdict: ⚠️ AVOID until regulated. Interesting mechanism, but not worth the risks of unverified products.

---

27. BPC-157 (Body Protection Compound)

What it is: Synthetic peptide derived from gastric juice protein Weight Loss Effect: None directly Use in stacks: Sometimes taken alongside GLP-1s to protect the gut lining from GI side effects Price: rupees 3,000–rupees 10,000 for 10mg vial Verdict: ⚠️ Unregulated. Limited human evidence. May help with gut health but no direct weight loss.

---

28. CJC-1295 + Ipamorelin

What it is: Growth hormone releasing peptide combination Claimed effect: Increases HGH → fat loss + muscle gain Price: rupees 5,000–rupees 15,000 for kit (grey market) Reality: Not proven for weight loss. Risk of insulin resistance with long-term use. Verdict: ❌ NO. Unregulated HGH stimulation is dangerous long-term.

---

29. Fragment 176-191

Same as AOD-9604. Often sold separately at rupees 1,500–rupees 6,000 per vial. Verdict: ⚠️ AVOID.

---

30. Research Peptides Summary

All research peptides (AOD-9604, BPC-157, CJC-1295, Fragment 176-191) are not approved for human use in India. They are sold on gray markets with no quality control. Do not use them. Wait for regulated approvals.

---

GLP-1 Comparison Table

Drug	Frequency	Weight Loss	India Price/Mo	Verdict
Tirzepatide	Weekly inj.	22%	rupees 8,000–rupees 20,000	🥇 Best
Semaglutide (Generic)	Weekly inj.	15%	rupees 1,300–rupees 4,500	🥈 Best Value
Rybelsus (Oral Sema)	Daily oral	12%	rupees 6,000–rupees 12,000	🥉 Oral Option
Dulaglutide	Weekly inj.	7%	rupees 4,000–rupees 5,700	✅ Heart benefit
Liraglutide	Daily inj.	8%	rupees 15,000–rupees 25,000	⚖️ Overpriced
Exenatide	Daily/Wkly	5%	rupees 3,000–rupees 6,000	❌ Superseded
CagriSema	Weekly inj.	22%	rupees 8,000–rupees 15,000 (est)	⏳ Wait
Orforglipron	Daily oral	12%	rupees 6,000–rupees 10,000 (est)	⏳ Wait
Retatrutide	Weekly inj.	24%	rupees 10,000–rupees 20,000 (est)	⏳ Wait

---

→ Continue to Part4: Experimental Peptides — Retatrutide, CagriSema & The Future